Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension

Abstract

The present invention relates to the use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension or pulmonary hypertension.

1 . A method for preventing or treating pulmonary arterial hypertension or pulmonary hypertension which comprises administering to a patient in need of such treatment an effective amount of irbesartan or a pharmaceutically acceptable salt thereof or solvate thereof.  
     
     
         2 . A method for preventing or treating pulmonary arterial hypertension or pulmonary hypertension which comprises administering to a patient in need of such treatment an effective amount of irbesartan or a pharmaceutically acceptable salt thereof or solvate thereof in combination with another active principle chosen from a diuretic agent an aquaretic agent, a vasodilator, an anticoagulant, a phosphodiesterase inhibitor, prostacyclin, or an endothelin receptor antagonist.  
     
     
         3 . A method according to  claim 2 , in which irbesartan or a pharmaceutically acceptable salt thereof or solvate thereof is combined with a diuretic.  
     
     
         4 . A method according to  claim 1  which comprises administering irbesartan.  
     
     
         5 . A method according to  claim 2  which comprises administering irbesartan in combination with another active principle.  
     
     
         6 . A method according to  claim 3  which comprises administering irbesartan in combination with a diuretic.  
     
     
         7 . A method according to  claim 4  for preventing or treating pulmonary arterial hypertension.  
     
     
         8 . A method according to  claim 7  for treating pulmonary arterial hypertension.  
     
     
         9 . A method according to  claim 7  for preventing pulmonary arterial hypertension.  
     
     
         10 . A method according to  claim 4  for preventing or treating pulmonary hypertension.  
     
     
         11 . A method according to  claim 10  for treating pulmonary hypertension.  
     
     
         12 . A method according to  claim 10  for preventing pulmonary hypertension.  
     
     
         13 . A method according to  claim 6  in which the diuretic is hydrochlorothiazide.  
     
     
         14 . A method according to  claim 5  in which the aquaretic agent is a vasopressin V 2  receptor antagonist.  
     
     
         15 . A method according to  claim 5  in which the endothelin receptor antagonist is bosentan.